Douglas T. Ross - Net Worth and Insider Trading

Douglas T. Ross Net Worth

The estimated net worth of Douglas T. Ross is at least $7,200 dollars as of 2023-04-01. Douglas T. Ross is the Chief Scientific Officer of OncoCyte Corp and owns about 20,317 shares of OncoCyte Corp (OCX) stock worth over $7,200. Details can be seen in Douglas T. Ross's Latest Holdings Summary section.

Transaction Summary of Douglas T. Ross


Douglas T. Ross Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Douglas T. Ross owns 1 companies in total, including OncoCyte Corp (OCX) .

Click here to see the complete history of Douglas T. Ross’s form 4 insider trades.

Insider Ownership Summary of Douglas T. Ross

Ticker Comapny Transaction Date Type of Owner
OCX OncoCyte Corp 2020-03-23 Chief Medical Officer

Douglas T. Ross Latest Holdings Summary

Douglas T. Ross currently owns a total of 1 stock. Douglas T. Ross owns 20,317 shares of OncoCyte Corp (OCX) as of March 25, 2022, with a value of $7,200.

Latest Holdings of Douglas T. Ross

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
OCX OncoCyte Corp 2022-03-25 20,317 0.35 7,200

Holding Weightings of Douglas T. Ross

Douglas T. Ross Form 4 Trading Tracker

According to the SEC Form 4 filings, Douglas T. Ross has made a total of 1 transactions in OncoCyte Corp (OCX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in OncoCyte Corp is the acquisition of 15,000 shares on March 25, 2022, which cost Douglas T. Ross around $21,000.

Insider Trading History of Douglas T. Ross

Insider Trading Shares
Shares Change
Final Share
Current Price
Price Change Since Insider Trade (%)
Filing Date
OncoCyte Corp
Total 1
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Douglas T. Ross Trading Performance

GuruFocus tracks the stock performance after each of Douglas T. Ross's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Douglas T. Ross is -27.14%. GuruFocus also compares Douglas T. Ross's trading performance to market benchmark return within the same time period. The performance of stocks bought by Douglas T. Ross within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Douglas T. Ross's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Douglas T. Ross

Average Relative Return

Outperforming Transactions

Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) -19.29 -27.14 -42.86 -81.43
Relative Return to S&P 500(%) -13.85 -13.24 -24.15 -68.84

Douglas T. Ross Ownership Network

Ownership Network List of Douglas T. Ross

No Data

Ownership Network Relation of Douglas T. Ross

Douglas T. Ross Owned Company Details

What does OncoCyte Corp do?

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.

Who are the key executives at OncoCyte Corp?

Douglas T. Ross is the Chief Medical Officer of OncoCyte Corp. Other key executives at OncoCyte Corp include Interim CEO Josh Riggs , Controller & PAO James Yang Liu , and SVP & Finance & and Interim CFO Anish M. John .

OncoCyte Corp (OCX) Insider Trades Summary

Over the past 18 months, Douglas T. Ross made no insider transaction in OncoCyte Corp (OCX). Other recent insider transactions involving OncoCyte Corp (OCX) include a net purchase of 11,964,028 shares made by Pura Vida Investments, Llc , a net purchase of 415,000 shares made by Andrew Arno , and a net purchase of 100,000 shares made by John Peter Gutfreund .

In summary, during the past 3 months, insiders sold 0 shares of OncoCyte Corp (OCX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 107,514 shares of OncoCyte Corp (OCX) were sold and 18,844,166 shares were bought by its insiders, resulting in a net purchase of 18,736,652 shares.

OncoCyte Corp (OCX)'s detailed insider trading history can be found in Insider Trading Tracker table.


OncoCyte Corp Insider Transactions

Total 0
Shares Owned
Trade Price($)
Trade Percentage(%)
Price change since trade(%)
Share ownership details
Filing Date
Total 0

Douglas T. Ross Mailing Address

Above is the net worth, insider trading, and ownership report for Douglas T. Ross. You might contact Douglas T. Ross via mailing address: 15 Cushing, Irvine Ca 92618.